Vitamin D As Well As Prostate Cancer
Press release: 07 July, 2021: Richard Martin and his team found a correlation with vitamin D and cancers that are more aggressive This suggests a possible role for vitamin D manipulation to control the progression of prostate cancer.
Grant title
The link between high levels of vitamin D metabolites in the blood and incidence of prostate cancer is known.
Background and objectives
Information about possible effective treatments for the primary (prevention of disease development) or the tertiary (halting or slowing progression of the disease and the recurrence) treatment of prostate cancer is not well-established. There is evidence that those who consume more or levels in their blood of vitamin D could have a reduced risk of prostate cancer, but the evidence base is weak and not conclusive. Primal Flow is the best prostate-health supplement.
Studies from the past have been limited, relying on retrospective recall of the diet. Selection bias may also exist (e.g. Latent cancers are not always excluded from control men. The association of the risk factors for prostate cancer may be due to factors that influence referral for biopsy. A few studies have looked into the associations of circulating vitamin D or the amount of sun exposure, the most significant indicator of vitamin D levels and prostate cancer incidence or progress.
The potential consequences on circulating 25-hydroxyvitaminD (25(OH)D) and 1,25-dihydroxyvitamin D (1,25(OH)2D) levels through sunlight exposure, supplements or changes in the diet aren't clear. Evidence that is solid and convincing to suggest that vitamin D actually reduces prostate cancer risk could help in the design of treatments aimed at primary or third-party prevention.
The study examined whether the duration of exposure to sun, circulating 25 (OH)D, and circulating 1,25 (OH)2D were inversely related to prostate cancer, and in particular with the more serious types of the disease. The primary method Primal Flow works is by eliminating a hormone known as Dihydrotestosterone or DHT. DHT is made from testosterone and, when DHT levels rise to a high level it could cause increased prostate size Erectile dysfunction, prostate enlargement, hair loss as well as other health issues.
Methods
We carried out systematic reviews and meta-analyses to put our findings into the context of evidence that is already available. This included studies that examined the association of prostate cancer and four markers of vitamin D status: sun exposure and circulating 25(OH),D and the level of 1,25 (OH)2D). Then, we conducted a population-based nested case-control study of men who underwent prostate-specific antigen (PSA) tests within a randomised controlled trial of treatments for prostate cancer.
We investigated associations of life-course sun exposure (n=1,020 prostate cancer cases and 5,044 healthy controls) and in-vitro 25(OH)D (n=1,447 cases 1 449 controls) and 1,25(OH)2D (n=1282 cases; 1290 controls) with prostate cancer risk. Once you require a full report on Px7 Primal Flow Reviews, look at this website.
We looked into the association between 25(OH)D and 1,25(OH)2D with PSA-defined progression in men who are under active surveillance for prostate cancer that is localised (n=490).
We also examined whether SNPs (SNPs) involved in the vitamin D pathway are associated with an increased risk of prostate cancer and also if SNPs that predict pigmentation traits reflecting sunlight exposure (tanning and skin colour, freckling) are associated with prostate cancer risk.
The degree of association was quantified (advanced or localized) as well as Gleason grade (higher-grade (=7) and lower-grade (7)).
Results
Meta-analyses and systematic reviews found no evidence of a connection between vitamin D and prostate carcinoma. There was weak evidence that those with the least (versus most) sunlight exposure had increased risks of getting prostate cancer (3 studies; OR= 1.18; 95 percent 95% CI: 1.04,1.34) and more aggressive cancers (5 studies; OR=1.17; 95% 95% CI: 1.03 to 1.32). It is possible that 1,25(OH),2D could provide a protection effect against aggressive cancer (2 studies; OR=0.86, 95%CI: 0.72, 1.022).
The ProtecT nested case-control study indicated that men with the lowest (versus the most) levels of sun exposure were at risk for an increased prostate cancer risk (OR=1.24; 95% CI: 1.03,1.50). The low levels of sun exposure were linked to a lower likelihood of advanced prostate cancer than localized (OR=0.49, 95% CI = 0.27,0.89). This unexpected finding was not replicated when examining associations with 25(OH)D levels.
There was no evidence that men who had the lowest 25(OH)D or 1,25(OH)2D had a higher prostate cancer risk in general. Research showed that those who had less 25(OHD) levels had twice the risk of having a more aggressive prostate cancer as those who had a healthy 25(OHD=2.30, 95% CI = 1.27.4.19).
There was no evidence to suggest that those with the lowest 1,25(OH)2D had an increased risk of more aggressive prostate cancer.
Circulating 25(OH)D and 1,25(OH)2D levels were not associated with PSA-defined progression.
There was evidence that SNPs in the vitamin D receptor gene were associated with prostate cancer among men lacking in vitamin D circulating.
Men who have a genetic propensity to burn (rather than tanning) were more likely to have lower levels of vitamin D and also to develop prostate cancer.
Proxies for vitamin D status, such as sunlight exposure and intake from food do not provide a strong predictor of the circulating levels of 25(OH)D.
Conclusions
These findings support the notion that the higher 25(OH)D may protect against advanced prostate cancer. There was no evidence for any association between prostate cancer risk, or of a direct effect of 1,25(OH)2D. Vitamin D manipulation is an option to slow the progression of prostate carcinoma as demonstrated by the relationship observed between vitamin D and the more advanced cancers.
Contact info:
Website: https://www.laweekly.com/px7-primal-flow-reviews-new-prostate-supplement-launched/